News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
Chu brings more than two decades of experience in product management, design and strategy, as well as expertise in navigating complex industries.
SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today named Daniel Chu to product manager position.
Prior to joining 23andMe, Chu served as Chief Product Officer at Waymo, where he launched the world’s first fully self-driving commercial ride-hailing service. He oversaw the product management, program management, user experience design and research, industrial design, product data science, and business strategy teams. Prior to Waymo, Chu led the Google Maps Platform product team, which included the Google Maps API, one of the most popular APIs available.
“Dan is a collaborative, data-driven leader who can build consumer products and services at scale. He has proven that he can navigate highly technical and regulated environments for consumer products. ‘welcome Dan as we grow our genomic health platform,’ said Anne Wojcicki, CEO and co-founder of 23andMe.
“I’m excited to join a founder-led, mission-driven company focused on using data to revolutionize health, wellness and research,” Chu said. “23andMe has helped make genetics mainstream and I look forward to joining the company as it embarks on transforming healthcare to provide a more personalized experience. 23andMe has a passionate team that creates impactful products and services that truly have the potential to help people live longer, healthier lives.
Chu holds a Bachelor of Science (BS) and a Bachelor of Arts (BA) from Stanford University, a Masters of Business Administration (MBA) from Harvard Business School, and a Masters in Public Administration (MPA) from Harvard Kennedy School.
23andMe is a genetics-focused consumer healthcare and therapy company delivering a healthier future. For more information, please visit www.23andMe.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation , statements regarding the future performance of 23andMe. companies in the field of genetics and consumer therapeutics as well as the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated into this press release, including statements regarding strategy, financial condition, funding of continuing operations, cash reserves, projected costs, plans and 23andMe’s management objectives, are forward-looking statements. . The words “believes”, “anticipates”, “estimates”, “plans”, “expects”, “intends”, “may”, “could”, “should”, “potential”, ” probable”, “projects”, “predicts”, “continues”, “will”, “plans” and “would” or, in each case, their negative or other variants or comparable terminology, are intended to identify forward-looking statements, although not all statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections regarding future events and various assumptions. 23andMe cannot guarantee that it will actually achieve any plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond 23andMe’s control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by such statements. prospective. The forward-looking statements contained herein are also generally subject to other risks and uncertainties that are described from time to time in the company’s filings with the Securities and Exchange Commission, including under Section 1A, “Factors of Risk” in the company’s most recent annual report. on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. The statements made herein are made as of the date of this press release and, except as required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments or otherwise. .
A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/515f0e84-3766-467c-91ec-e93d42b4411a